Clarix Imaging Enters into Know-How Agreement with Mayo Clinic in Surgical Oncology and Radiology

Clarix Imaging®, a pioneering force in surgical oncology, proudly announces a collaboration with Mayo Clinic to catalyze new surgical advancements using Clarix Imaging’s proprietary and patented volumetric specimen imaging hardware and software technology.

Collaboration aims to enhance patient care during breast cancer surgery

CHICAGO--(BUSINESS WIRE)-- Clarix Imaging®, a pioneering force in surgical oncology, proudly announces a collaboration with Mayo Clinic to catalyze new surgical advancements using Clarix Imaging’s proprietary and patented volumetric specimen imaging hardware and software technology. Clarix Imaging’s technology generates true 3D images of surgical specimens intraoperatively. The aim of the know-how agreement with Mayo Clinic is to develop novel clinical solutions to enhance patient care during breast cancer surgery.

“While traditional medical imaging provides images as the end product, Clarix Imaging’s innovative solution creates 3D images that also serve as the foundation for future value-added products and services,” Clarix Imaging’s CEO and co-founder, Dr. Xiao Han, PhD, said. “We perceive promising potential within our platform, and this collaboration will accelerate our scientific and engineering endeavors and enable exploration of new avenues that further enhance its clinical value and improve patient care.”

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

About Clarix Imaging

Clarix Imaging® is an NIH-funded and venture-backed private company founded by world-renowned medical imaging scientists from the University of Chicago (UC). Rooted in decades of cutting-edge research at UC in medical imaging theory, techniques, and artificial intelligence, as well as the team’s breakthrough innovations in tomographic imaging algorithms and systems, the company’s mission is to empower clinicians with clear tumor visualization and intelligent analysis for precision and personalized medicine. Clarix Imaging’s first flagship product is the FDA-cleared Volumetric Specimen Imager (VSI-360), which offers unprecedented clarity in intraoperative specimen margin visualization in breast cancer surgeries such as lumpectomy. It places the power of true 3D specimen imaging right at the fingertips of surgeons and radiologists in real time. Unrivaled with its precision and workflow-oriented software, VSI-360 generates a true 3D representation of the specimen and allows users to visualize the tumor in thin image slices without overlapping tissues obscuring the margins.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231026131474/en/

Contacts

Deanna Barnert
pr@clariximaging.com
(310)-710-2906

Source: Clarix Imaging

Powered by Business Wire

View this news release online at:
http://www.businesswire.com/news/home/20231026131474/en

MORE ON THIS TOPIC